Search results
Results from the WOW.Com Content Network
The big pharmaceutical company provided a disappointing Q3 update.
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling. And now the ...
Lilly and Novo Nordisk (NYSE: NVO) are dominant in most markets right now, but that won't be the case much longer. Roche's latest announcement is one example, but the list includes a crowd of ...
Here's what happened and why Eli Lilly stock is still worth buying. ... the bad news: Lilly slightly cut its guidance for 2024. Whereas it previously anticipated bringing in as much as $46.6 ...
Eli Lilly missed Wall Street's revenue expectations in its third quarter earnings released Wednesday morning, which sent shares down more than 6%.The drugmaker also slashed its profit guidance and ...
Making headway against the competition: Right now, the biggest names in obesity care are Novo Nordisk's (NYSE: NVO) Wegovy and Lilly's Zepbound. In a recent study, Lilly found that Zepbound ...
Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update are overblown It's not surprising that Lilly's shares sank after its Q3 update.
Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs. This morning ...